Belite Bio, Inc (BLTE) stock analysis
In our weekly check, Belite Bio, Inc is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 9 pass, warnings: 1, red flags: 8.
About Belite Bio, Inc
Belite Bio, Inc is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as BLTE.
What our checks show for BLTE
Red flags
- Weak EPS growth
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 52.6% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 75% from a peak. Would you have held through that?
- The share count grew by 26.1% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Thinly traded (about 182 thousand shares a day): buying and selling can move the price.
Strengths
- Debt is low: 0x equity.
- Analysts expect earnings per share to grow about 36.5% a year over the next years.
- Analysts expect the net margin to improve by 56.7 points from today's 0%.
- After its deepest fall the stock recovered in about 6 months.
- Beta -1.19: the stock usually moves less than the market.
Similar companies
CAI · CGON · ARWR · IBRX · KOD · TXG
Questions
What grade does Belite Bio, Inc (BLTE) have?
In our weekly check, Belite Bio, Inc is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 9 pass, warnings: 1, red flags: 8. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of BLTE stock?
This week's biggest flags for Belite Bio, Inc: Weak EPS growth, Thin margins, Weak free cash flow. In total 9 of 18 checks show a warning or a red flag.
What does Belite Bio, Inc do?
Belite Bio, Inc is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as BLTE.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis